The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $58.14 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $57.37, down -1.32%. In other words, the price has decreased by -$1.32 from its previous closing price. On the day, 1.27 million shares were traded. GMED stock price reached its highest trading level at $58.3 during the session, while it also had its lowest trading level at $57.18.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.86. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On January 10, 2025, BofA Securities Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $97.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 7766693376 and an Enterprise Value of 7398238720. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 42.91, and their Forward P/E ratio for the next fiscal year is 15.46. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.09 while its Price-to-Book (P/B) ratio in mrq is 1.90. Its current Enterprise Value per Revenue stands at 2.947 whereas that against EBITDA is 10.266.
Stock Price History:
The Beta on a monthly basis for GMED is 1.21, which has changed by -0.14373136 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $54.48. The 50-Day Moving Average of the stock is -11.36%, while the 200-Day Moving Average is calculated to be -23.92%.
Shares Statistics:
The stock has traded on average 1.46M shares per day over the past 3-months and 1049690 shares per day over the last 10 days, according to various share statistics. A total of 112.93M shares are outstanding, with a floating share count of 112.16M. Insiders hold about 17.15% of the company’s shares, while institutions hold 82.34% stake in the company. Shares short for GMED as of 1748563200 were 5163596 with a Short Ratio of 3.53, compared to 1745971200 on 4215167. Therefore, it implies a Short% of Shares Outstanding of 5163596 and a Short% of Float of 5.12.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
